I-MAB (IMAB) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
I-Mab, a global biotech firm focused on cancer immunotherapies, has appointed Sean Fu as its permanent CEO. With over 20 years in the life sciences industry, Fu aims to advance I-Mab’s clinical programs and strategy. His leadership is expected to drive the company towards significant milestones in the development of transformative therapies.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
